Hypothalamic hormones: From neuroendocrinology to cancer therapy

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The discovery of hypothalamic hormones, especially LH-RH and somatostatin has led to practical clinical use of their analogs in the field of cancer treatment. Bombesin/GRP antagonists can be also considered for the development of new methods for treatment of various tumors. The understanding of functions of these peptide hormones and the availability of their synthetic analogs should permit the clinicians to treat a variety of cancers more successfully than in the past.

Original languageEnglish
Pages (from-to)115-130
Number of pages16
JournalAnti-Cancer Drugs
Volume5
Issue number2
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Neuroendocrinology
Hypothalamic Hormones
Bombesin
Neoplasms
Peptide Hormones
Somatostatin
Gonadotropin-Releasing Hormone
Therapeutics

Keywords

  • antitumor activity
  • bombesin/gastrin releasing peptide
  • corticotropin-releasing factor
  • cytotoxic peptide analogs
  • luteinizing hormone-releasing hormone
  • somatostatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Cite this

Hypothalamic hormones : From neuroendocrinology to cancer therapy. / Schally, Andrew V.

In: Anti-Cancer Drugs, Vol. 5, No. 2, 01.01.1994, p. 115-130.

Research output: Contribution to journalArticle

@article{efde1d2c546b4d7b8a8f25b762f791ac,
title = "Hypothalamic hormones: From neuroendocrinology to cancer therapy",
abstract = "The discovery of hypothalamic hormones, especially LH-RH and somatostatin has led to practical clinical use of their analogs in the field of cancer treatment. Bombesin/GRP antagonists can be also considered for the development of new methods for treatment of various tumors. The understanding of functions of these peptide hormones and the availability of their synthetic analogs should permit the clinicians to treat a variety of cancers more successfully than in the past.",
keywords = "antitumor activity, bombesin/gastrin releasing peptide, corticotropin-releasing factor, cytotoxic peptide analogs, luteinizing hormone-releasing hormone, somatostatin",
author = "Schally, {Andrew V}",
year = "1994",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "115--130",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Hypothalamic hormones

T2 - From neuroendocrinology to cancer therapy

AU - Schally, Andrew V

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The discovery of hypothalamic hormones, especially LH-RH and somatostatin has led to practical clinical use of their analogs in the field of cancer treatment. Bombesin/GRP antagonists can be also considered for the development of new methods for treatment of various tumors. The understanding of functions of these peptide hormones and the availability of their synthetic analogs should permit the clinicians to treat a variety of cancers more successfully than in the past.

AB - The discovery of hypothalamic hormones, especially LH-RH and somatostatin has led to practical clinical use of their analogs in the field of cancer treatment. Bombesin/GRP antagonists can be also considered for the development of new methods for treatment of various tumors. The understanding of functions of these peptide hormones and the availability of their synthetic analogs should permit the clinicians to treat a variety of cancers more successfully than in the past.

KW - antitumor activity

KW - bombesin/gastrin releasing peptide

KW - corticotropin-releasing factor

KW - cytotoxic peptide analogs

KW - luteinizing hormone-releasing hormone

KW - somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0028352250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028352250&partnerID=8YFLogxK

M3 - Article

C2 - 8049494

AN - SCOPUS:0028352250

VL - 5

SP - 115

EP - 130

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -